Evidence map›Paper›PMID 36065073›Full record

ArticleHepatology international2022

Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC.

Yixiu Wang, Yongfa Zhang, Longrong Wang, Ning Zhang, Weiqi Xu, Jiamin Zhou, Yiming Zhao, Weiping Zhu, Ti Zhang, Lu Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yixiu Wang *Qingdao Institute，Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yongfa Zhang *Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Longrong Wang *Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Ning ZhangDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Weiqi XuDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Jiamin ZhouDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yiming ZhaoDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Weiping ZhuDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. wpzhush@126.com.
Ti ZhangDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. zhangti@shca.org.cn.
Lu WangDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. wangluzl@fudan.edu.cn.
Fudan University Shanghai Cancer Center · CN

Funding

Clinical Research Plan of SHDC SHDC2020CR4018National Natural Science Foundation of China 81874182National Natural Science Foundation of China 81902907Shanghai Pujiang Program 2019PJD008
6 · The paper itself

Abstract

backgroundCuproptosis is a recently discovered mechanism of programmed cell death caused by intracellular aggregation of mitochondrial lipoylated proteins and destabilization of iron-sulfur proteins triggered by copper. Hepatocellular carcinoma (HCC) is a common malignant tumor with a poor prognosis. We aimed to predict the survival of patients with HCC using the cuproptosis-related gene (CRG) expression.

methodsWe analyzed the expression, methylation, and mutation status of CRGs in 538 HCC patients and correlated the date with clinical prognosis. HCC patients were divided into two clusters based on their CRG expression. The relationship between CRGs, risk genes, and the immune microenvironment was analyzed using the CIBERSORT algorithm and the single-cell data analysis method. A cuproptosis risk model was constructed according to the five risk genes using the LASSO COX method. To facilitate the clinical applicability of the proposed risk model, we constructed a nomogram and conducted an antineoplastic drug sensitivity analysis.

resultsOur results suggest that the expression levels of CRGs in HCC are regulated by methylation. The prognoses were significantly different between the patients of the two clusters. The prognostic risk score positively correlated with memory T cell activation and negatively correlated with natural killer (NK) and regulatory T cell activation.

conclusionOur findings indicate the involvement of CRG regulation in HCC and provide new insights into prognosis assessment. Drug sensitivity analysis predicted drug candidates for the treatment of patients with different HCC subtypes.

Indexed as

ApoptosisCarcinoma, HepatocellularLiver NeoplasmsBiomarkers, TumorCopperGene Expression Regulation, NeoplasticHumansPrognosisTumor MicroenvironmentBiomarkers, TumorCopperCuproptosisDrug sensitivity analysisHepatocellular carcinomaImmune microenvironmentMolecular subtypesNomogramSingle-cell data analysisSurvival prognosisTumor metabolismTumor microenvironment

Identifiers

PMID36065073
OpenAlexW4294643326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.